About Apica Cardiovascular
Apica Cardiovascular is a Healthcare company based in Galway (Ireland) founded in 2009, and was acquired by Thoratec in July 2014. Transapical surgical access devices for heart procedures are developed. Apica Cardiovascular has raised $5.1 million across 1 funding round from investors including Thoratec, Seroba Lifesciences and Triventures. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices.
Company details
Apica developed a suite of implant systems and devices designed to enable transapical surgical access. These include devices for transapical delivery of therapeutic devices. Transapical access to the heart is often needed for procedures such as Transcatheter Aortic Valve Implantation (TA-TAVI) and Mitral Valves replacement. The company was acquired in July 2014 by Thoratec for an upfront cash payment of 35 million and potential future clinical and sales milestones of up to 40 million.
Funding Insights of Apica Cardiovascular
Apica Cardiovascular has successfully raised a total of $5.1M through 1 strategic funding round. The most recent funding activity was a Series A round of $5.1 million completed in January 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.1M
- Total Rounds 1
- Last Round Series A — $5.1M
- First Round $5.1M
(Jan 2011)
- Investors Count 2
All 1 funding rounds of Apica Cardiovascular with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2011 | $5.1M | Series A | – | – |
3 investors in total: 3 institutional.
Investors in Apica Cardiovascular
Apica Cardiovascular has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Thoratec, Seroba Lifesciences and Triventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in early stage healthcare startups | triventures.vc | Herzliya, Israel | ||
Seroba Lifesciences is focused on life sciences venture capital investments. | seroba-lifesciences.com | Dublin, Ireland | ||
Proprietary medical devices for circulatory support are developed and marketed. | 1979 | thoratec.com | Pleasanton, United States |
Investor details for Apica Cardiovascular
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Apica Cardiovascular
3 dated milestones of Apica Cardiovascular across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Apica Cardiovascular is founded.
- Funding First funding round of $5.1M.
- Exit Acquired by Thoratec.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Apica Cardiovascular
Apica Cardiovascular was founded in 2009 and raised its 1st funding round 2 years after it was founded.
Apica Cardiovascular is headquartered in Galway, Ireland.
Apica Cardiovascular is a funded company, having raised a total of $5.1M across 1 funding round to date. The company's 1st funding round was a Series A of $5.1M, raised on Jan 2011.
Apica developed a suite of implant systems and devices designed to enable transapical surgical access. These include devices for transapical delivery of therapeutic devices. Transapical access to the heart is often needed for procedures such as Transcatheter Aortic Valve Implantation (TA-TAVI) and Mitral Valves replacement. The company was acquired in July 2014 by Thoratec for an upfront cash payment of 35 million and potential future clinical and sales milestones of up to 40 million.
Apica Cardiovascular has 3 investors. Key investors include Thoratec, Seroba Lifesciences, and Triventures.
Yes. Apica Cardiovascular was acquired by Thoratec in July 2014.